Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis

Borchers, 2012, Lupus nephritis: a critical review, Autoimmun Rev, 12, 174, 10.1016/j.autrev.2012.08.018 Aurinia Pharmaceuticals. Aurinia announces voclosporin meets 48-week remission endpoints, achieving highest complete remission rate of any global lupus nephritis study. Available at: http://ir.auriniapharma.com/press-releases/detail/73. Accessed July 25, 2017. Bomback, 2016, Complement-mediated glomerular diseases: a tale of 3 pathways, Kidney Int Rep, 1, 148, 10.1016/j.ekir.2016.06.005 Sato, 2011, Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis, Lupus, 20, 1378, 10.1177/0961203311415561 Wang, 1996, Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5, Proc Natl Acad Sci U S A, 93, 8563, 10.1073/pnas.93.16.8563 Sciascia, 2017, Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence, Rheumatol Int, 37, 1249, 10.1007/s00296-017-3686-5 Biesecker, 1981, Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis, J Exp Med, 154, 1779, 10.1084/jem.154.6.1779 Falk, 1983, Neoantigen of the polymerized ninth component of complement, J Clin Invest, 72, 560, 10.1172/JCI111004 Teixeira, 1996, CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients, Clin Exp Immunol, 105, 497, 10.1046/j.1365-2249.1996.d01-776.x Nisihara, 2013, Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients, Hum Immunol, 74, 907, 10.1016/j.humimm.2013.04.030 Wang, 2018, Membrane attack complex (MAC) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment, Semin Arthritis Rheum, 48, 256, 10.1016/j.semarthrit.2018.01.004 Porcel, 1995, The value of complement activation products in the assessment of systemic lupus erythematosus flares, Clin Immunol Immunopathol, 74, 283, 10.1006/clin.1995.1040 Xing, 2010, Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis, J Clin Immunol, 30, 144, 10.1007/s10875-009-9344-2 Pickering, 2015, Eculizumab as rescue therapy in severe resistant lupus nephritis, Rheumatology (Oxford), 54, 2286 Herlitz, 2012, Pathology after eculizumab in dense deposit disease and C3 GN, J Am Soc Nephrol, 23, 1229, 10.1681/ASN.2011121186 Timmermans, 2018, C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension, J Am Soc Nephrol, 29, 2234, 10.1681/ASN.2018020184 de Holanda, 2017, Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3: a case report and systematic review, Clin Rheumatol, 36, 2859, 10.1007/s10067-017-3823-2 Clinical Commissioning Policy: Eculizumab in the treatment of recurrence of C3 glomerulopathy post-kidney transplant (all ages). Reference: NHS England: 16054/P. Available at: https://www.england.nhs.uk/wp-content/uploads/2017/02/clin-comms-policy-16054p.pdf. Accessed November 29, 2018. Schulze, 1993, Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis, Am J Pathol, 142, 179